Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia

Bone Marrow Transplantation

Volumn 34, Issue 9, 2004, Pages 799-806

  Nemecek, E R ^a   Gooley, T A ^a   Woolfrey, A E ^a   Carpenter, P A ^a   Matthews, D C ^a   Sanders, J E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Childhood leukemia

Indexed keywords

ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTITIS; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DERMATITIS; ENTERITIS; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 7944220987     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704689     Document Type: Article

References (43)

1. Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
2. Amadori S, Testi AM, Arico M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11: 1046-1054.
3. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
4. Feig SA, Lampkin B, Nesbit ME et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children's Cancer Group. Bone Marrow Transplant 1993; 12: 65-71.
5. Wells RJ, Woods WG, Buckley JD et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children's Cancer Group study. J Clin Oncol 1994; 12: 2367-2377.
6. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428-1434.
7. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101 130-140.
8. Fleischhack G, Hasan C, Graf N et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102: 647-655.
9. Dini G, Boni L, Abla O et al. Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Bone Marrow Transplant 1994; 13: 771-776.
10. Schiller G, Feig SA, Territo M et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 1994; 88: 72-78.
11. Aladjidi N, Auvrignon A, Leblanc T et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377-4385.
12. Webb DK, Wheatley K, Harrison G et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999; 13: 25-31.
13. Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404.
14. Woolfrey AE, Gooley TA, Sievers EL et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998; 92 3546-3556.
15. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2354-2363.
16. Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997; 15: 557-565.
17. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
18. Dinndorf P, Bunin N. Bone marrow transplantation for children with acute myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 211-224.
19. Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
20. Horowitz MM, Bortin MM. Results of bone marrow transplants from human leukocyte antigen-identical sibling donors for treatment of childhood leukemias. A report from the International Bone Marrow Transplant Registry. Am J Pediatr Hematol Oncol 1993; 15: 56-64.
21. Brochstein JA, Kernan NA, Groshen S et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317: 1618-1624.
22. Balduzzi A, Valsecchi MG, Silvestri D et al. Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 2002; 29: 93-100.
23. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
24. Webb DK, Harrison G, Stevens RF et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714-1720.
25. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
26. Hansen JA, Mickelson EM, Choo SY et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In: Rose NR, De Macario EC, Fahey JL, Friedman H, Penn GM (eds). Manual of Clinical Laboratory Immunology. American Society for Microbiology: Washington, DC, 1992, pp 850-866.
27. Dupont B, Yang SY. Histocompatibility. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, MA, 1994; pp 22-40.
28. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 895-902.
29. Storb R, Deeg HJ, Whitehead J et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 1987; 19: 2608-2613.
30. Common Toxicity Criteria Manual Version 2, Cancer Therapy Evaluation Program, National Institutes of Health, National Cancer Institute, 1999.
31. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
32. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
34. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, NY, 1980.
35. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-1729.
36. Fung HC, Stein A, Slovak M et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 9: 766-771.
37. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-4235.
38. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
39. Svennilson J, Remberger M, Ringden O. Risk factors for moderate-to-severe acute graft-vs-host disease after allogeneic stem cell transplantation in children. Pediatr Transplant 2003; 7: 130-136.
40. Locatelli F, Uderzo C, Dini G et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627-633.
41. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991, 324.
42. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
43. Jonson FL, Hartmann JR, Thomas ED et al. Marrow transplantation in treatment of children with aplastic anaemia or acute leukaemia. Arch Dis Child 1976; 51: 403-410.